Paradromics has launched the Application Expansion (APEX) Partnership Program, a structured collaboration with five academic research centres designed to push its Connexus brain-computer interface into clinical areas beyond its initial speech-restoration mandate. The partners include Stanford University, Massachusetts General Hospital, the University of Pittsburgh, UC Davis, and the University of Michigan.
The move comes as Paradromics prepares to begin its Connect-One early feasibility study, the first-in-human clinical trial of a fully implantable BCI designed specifically to restore speech. The FDA granted investigational device exemption approval in November 2025, and the company has said it plans to enrol its first two patients from three clinical sites in early 2026.
What APEX Covers
The partnership programme gives academic researchers access to Paradromics’ Connexus hardware platform for use in their own BCI studies. The goal is to expand the clinical scope of the device beyond speech into stroke neurorecovery, Parkinson’s disease, movement disorders, and broader motor rehabilitation.
At Stanford, Dr. Jamie Henderson — a pioneer in image-guided functional neurosurgery for movement disorders — will lead work on multi-regional brain targeting protocols. At Massachusetts General Hospital, Dr. Daniel Rubin, who directs the country’s first dedicated BCI clinic, will evaluate Connexus for neurorecovery and expanded communication applications. The University of Pittsburgh, UC Davis, and the University of Michigan round out the network.
Paradromics’ chief scientific officer Vikash Gilja described the programme as building “a vibrant ecosystem where scientific discovery and medical device development move hand-in-hand.” The company hopes APEX-driven research will produce clinical trial-ready applications by 2027.
The Connexus Platform
The Connexus BCI uses micro-electrodes, each thinner than a human hair, implanted in the motor cortex to capture individual neuron activity. Signals are routed to an implanted chest receiver, transmitted wirelessly through the skin, and processed by an external computer running AI-based speech decoding. In preclinical testing, the system achieved an information transfer rate exceeding 200 bits per second and demonstrated three years of stable recordings.
The device’s architecture — titanium and platinum-iridium construction, fully implanted with no external cables — differentiates it from competitors that rely on percutaneous connectors. Paradromics completed its first acute human implant at the University of Michigan in June 2025, confirming the device could be surgically placed and record neural signals in a human brain.
Why Academic Partnerships Matter
Most BCI companies partner with individual research labs on an ad hoc basis. Paradromics is formalising the relationship across multiple institutions simultaneously, which creates a broader evidence base for regulatory submissions and accelerates the exploration of new indications.
The strategy also hedges the company’s clinical risk. If Connexus proves effective for speech restoration but the market is limited to a small patient population, having parallel research tracks in stroke, Parkinson’s, and motor rehabilitation opens significantly larger commercial pathways. The Parkinson’s disease market alone is projected to exceed $8 billion by 2030.
Paradromics has not disclosed the financial terms of the APEX agreements or total company funding. CEO Matt Angle has previously described Connexus as “the best engineered brain-computer interface in the world.” The APEX programme is his bet that academic researchers, given access to the hardware, will prove him right across multiple therapeutic domains.
The Competitive Picture
The timing is notable. Neuralink has twenty-one patients implanted and is expanding into visual restoration with Blindsight. Synchron’s endovascular approach has attracted attention for its lower surgical risk. BrainGate, housed at the same Massachusetts General Hospital where Paradromics’ APEX partner Daniel Rubin works, just published record-setting typing results in Nature Neuroscience this week.
Paradromics’ approach is distinct: rather than pursuing a single high-profile indication, it is building a platform play — one device architecture, many clinical applications, validated by independent academic centres. Whether that strategy delivers depends on whether Connexus performs as well in human trials as it has in preclinical work. The Connect-One study will begin to answer that question.